Optimal Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
The following is a summary of “Comparative efficacy and safety of first-line neoadjuvant therapy...
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 1204 results for 'non-small cell lung cancer'
Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer.
Immunotherapy is improving the survival of patients with metastatic non-small cell lung cancer (NSCLC), yet reliable biomarkers are needed to identify responders prospectively and optimize patient care. In this study, we explore...
Read More
RAMOSE Phase II trial finds promising results for osimertinib and ramucirumab in non-small cell lung cancer
1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor...
Read More
Perioperative Pembrolizumab Improves Survival in Resectable Early-Stage Non-Small Cell Lung Cancer
1. 36-month overall survival and median event-free survival were significantly greater in the...
Read More
Mutation-Driven Metastatic Patterns in Non-Small Cell Lung Cancer
The following is a summary of “Association of mutation profiles with metastasis in patients with...
Read MoreUSP5 Stabilizes IKBKG Through Deubiquitination to Suppress Ferroptosis and Promote Growth in Non-small Cell Lung Cancer.
Ferroptosis, a distinctive modality of cell mortality, has emerged as a critical regulator in non-small cell lung cancer (NSCLC). The deubiquitinating enzyme USP5 has established an oncogenic role in NSCLC. However, its...
Read MoreClinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor.
Immune checkpoint inhibitors (ICIs) have been approved as first-line therapy for advanced non-small cell lung cancer (NSCLC). The probiotic MIYAIRI 588 can potentially improve the outcomes of patients with advanced NSCLC treated...
Read More
MIS Resection After Neoadjuvant Therapy in Non-Small Cell Lung Cancer
The following is a summary of “Determinants of successful minimally invasive surgery (MIS) for...
Read MoreConstruction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer.
Patients with non-small cell lung cancer (NSCLC) with liver metastasis have a poor prognosis, and there are no reliable biomarkers for predicting disease progression. Currently, no recognized and reliable prediction model exists...
Read MoreAdvertisement
EGFR mutations induce the suppression of CD8 T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) patients with EGFR mutations exhibit an unfavorable response to immune checkpoint inhibitor (ICI) monotherapy, and their tumor microenvironment (TME) is usually immunosuppressed. TGF-β plays an...
Read More
Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
1. Treatment with osimertinib significantly improved progression-free survival, compared to...
Read MoreNovel therapeutic strategies for rare mutations in non-small cell lung cancer.
Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of...
Read More
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
MONDAY, April 22, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved...
Read More[Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
To describe the clinical characteristics of patients with non-small cell lung cancer (NSCLC) who developed checkpoint inhibitor pneumonitis (CIP) and to explore potential prognostic factors. NSCLC patients who were complicated...
Read MoreCost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
There are differences in the pharmacoeconomics of Immune checkpoint blocking (ICB) therapies for the treatment of lung squamous cell carcinoma (LSCC). However, no corresponding review studies have fully discussed the...
Read MoreStereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study.
To analyze the efficacy of stereotactic ablative brachytherapy (SABT) and percutaneous microwave ablation (MWA) for the treatment of early-stage non-small cell lung cancer (NSCLC).Patients with early-stage (T1-T2aN0M0) NSCLC who...
Read MorecircEPB41L2 blocks the progression and metastasis in non-small cell lung cancer by promoting TRIP12-triggered PTBP1 ubiquitylation.
The metastasis of non-small cell lung cancer (NSCLC) is the leading death cause of NSCLC patients, which requires new biomarkers for precise diagnosis and treatment. Circular RNAs (circRNAs), the novel noncoding RNA, participate...
Read More
Influence of Concurrent Genetic Changes on Patient Outcomes in ALK-Rearranged Non-Small Cell Lung Cancer
The following is a summary of “Impact of Concurrent Genomic Alterations on Clinical Outcomes in...
Read MoreAstragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD Axis.
Astragaloside IV (AS-IV) has been shown to have a curative effect on non-small cell lung cancer (NSCLC). This study aimed to elucidate the role of AS-IV in NSCLC cell anlotinib resistance (AR).The NSCLC/AR cells, resistant to...
Read MoreIruplinalkib (WX-0593) versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
Iruplinalkib (WX-0593) is a new-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) and has shown systemic and central nervous system (CNS) efficacy in ALK-positive non-small-cell lung cancer...
Read More